公开(公告)号：US20210355213A1

公开(公告)日：2021-11-18

申请号：US17381418

申请日：2021-07-21

Applicant: INNATE PHARMA

Inventor： HATEM ABDELAZIM ,  CARINE PATUREL

IPC: C07K16/28 ,  A61K31/7068 ,  A61K31/282 ,  G01N33/574 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to methods for the treatment of T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and/or oxaliplatin. The treatments are particularly useful in the treatment of peripheral T cell lymphomas, for example PTCL-NOS.

公开(公告)号：US20210340254A1

公开(公告)日：2021-11-04

申请号：US17376314

申请日：2021-07-15

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  NICOLAS SCHNEIDER

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US20200369764A1

公开(公告)日：2020-11-26

申请号：US16629585

申请日：2018-07-09

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

公开(公告)号：US10688180B2

公开(公告)日：2020-06-23

申请号：US15703126

申请日：2017-09-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  Innate Pharma

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton ,  Pascale Andre

IPC: C07K16/00 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

公开(公告)号：US20200024357A1

公开(公告)日：2020-01-23

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US20190248895A1

公开(公告)日：2019-08-15

申请号：US16343796

申请日：2017-10-19

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/00 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: This disclosure relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20190031755A1

公开(公告)日：2019-01-31

申请号：US16071499

申请日：2017-01-20

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CAROLINE DENIS ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.

公开(公告)号：US10160810B2

公开(公告)日：2018-12-25

申请号：US14594353

申请日：2015-01-12

Applicant: INNATE PHARMA, S.A. ,  UNIVERSITY OF GENOVA

Inventor： Alessandro Moretta ,  Emanuela Marcenaro ,  Francois Romagne ,  Pascale Andre

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  G01N33/569 ,  A61K39/00

Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

公开(公告)号：US20180355036A1

公开(公告)日：2018-12-13

申请号：US16066688

申请日：2016-12-20

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  NADIA ANCERIZ ,  ARIANE MOREL ,  BENJAMIN ROSSI

IPC: C07K16/28 ,  C07K16/46

CPC classification number: C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92

Abstract: NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US09944712B2

公开(公告)日：2018-04-17

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.